Overview
GHRP-6 is the original and most well-characterized growth hormone releasing peptide, a synthetic hexapeptide that acts on the ghrelin receptor. It produces potent GH secretion accompanied by the most pronounced appetite stimulation of any GHRP — often described as an intense, sudden hunger surge within 15–20 minutes of injection. Widely studied in preclinical models for cytoprotective effects.
Mechanism of action
GHRP-6 is a met-enkephalin analog that acts as a full agonist at the ghrelin receptor (GHSR-1a), the same receptor activated by endogenous ghrelin. Binding activates protein kinase C (PKC) and mobilizes intracellular calcium via the inositol trisphosphate/diacylglycerol (IP3/DAG) pathway, triggering pulsatile GH release from pituitary somatotrophs. GHRP-6 also suppresses somatostatin signaling to further amplify GH output. In the hypothalamus, GHSR-1a activation stimulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus — the primary orexigenic (appetite-driving) circuit — producing hunger that is more intense than any other GHRP. Beyond GH secretion, GHRP-6 has demonstrated cytoprotective, anti-apoptotic, and anti-inflammatory effects in cardiac and hepatic tissue in preclinical models, mediated partly through CD36 receptor interactions independent of GHSR-1a.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| GH stimulation and muscle growth | subcutaneous | 100–300 mcg | 2–3 times daily | Inject on an empty stomach 3 times daily. Intense hunger within 15–20 minutes of injection is expected and users often plan meals accordingly. Commonly combined with a GHRH analog for synergistic GH release. |
| appetite stimulation / weight gain | subcutaneous | 150–300 mcg | once to twice daily pre-meal | Users seeking appetite stimulation (e.g., hardgainers or during bulking phases) may inject 30 minutes before large meals. The strong ghrelin-mimicking appetite effect is a defining feature of GHRP-6 versus other GHRPs. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
GHRP-6 was the peptide that led to the discovery of the ghrelin receptor, establishing the mechanistic foundation for the entire GHRP class. Decades of preclinical studies document GH secretagogue activity, cardiomyocyte protection, and hepatocellular cytoprotection. A notable rat model of myocardial infarction demonstrated reduced infarct size and improved cardiac function. A small human trial confirmed robust GH secretion dose-dependently. No large-scale human clinical trials for anabolic or cytoprotective indications have been completed. Community use is extensive for muscle building, injury recovery, and GH optimization.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with GHRP-6 for synergistic effects.
Legal status
GHRP-6 was placed on the FDA Category 2 bulk drug substance list in September 2023, banning compounding pharmacy preparation in the US. Industry analysis as of February 2026 indicates GHRP-6 is among the ~5 peptides expected to remain on Category 2 (alongside GHRP-2, Melanotan II, LL-37, and PEG-MGF) due to cortisol/prolactin elevation and appetite stimulation concerns. No formal FDA update published as of April 2026.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.